首页> 外文期刊>Journal of the American College of Surgeons >Optimizing Risk Stratification in Portal Vein Thrombosis after Splenectomy and its Primary Prophylaxis with Antithrombin III Concentrates and Danaparoid Sodium in Liver Cirrhosis with Portal Hypertension
【24h】

Optimizing Risk Stratification in Portal Vein Thrombosis after Splenectomy and its Primary Prophylaxis with Antithrombin III Concentrates and Danaparoid Sodium in Liver Cirrhosis with Portal Hypertension

机译:脾切除术后优化门静脉血栓形成的风险分层及其肝硬化肝硬化中抗凝血酶III浓缩物和DanaParoid钠的初前预防肝硬化

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Decreased antithrombin III (ATIII) activity and large splenic vein diameter (SVD) are risk factors for portal vein thrombosis (PVT) after splenectomy in liver cirrhosis with portal hypertension. Antithrombin III concentrates can prevent PVT. This study was designed to stratify risks for PVT after splenectomy in cirrhotic patients and to develop prophylactic protocols for PVT.
机译:背景:减少抗凝血酶III(ATIII)活性和大的脾静脉直径(SVD)是肝硬化患者门静脉患者肝硬化后门静脉血栓形成(PVT)的危险因素。 抗凝血酶III浓缩物可以防止PVT。 本研究旨在将PVT在肝硬化患者患病后的PVT的风险分层,并为PVT开发预防方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号